Jan 18, 2024 Biotech settlement agreements – a competition law checklist By Sophie Lawrance Sean-Paul Brankin This article is part of our Biotech Review of the Year - Issue 11 publication Introduction The European Commission (EC) published its...
Jan 18, 2024 Strategic considerations for partnering with CDMOs for cell and gene therapies By Claire Smith Erik Müürsepp This article is part of our Biotech Review of the Year - Issue 11 publication The biopharmaceutical landscape is undergoing a steady but...
Jan 18, 2024 Royalty monetisation – why some biotechs are turning to royalty aggregators to help unlock the future value of their out-licensed technology By Marek Petecki Ellen Lambrix This article is part of our Biotech Review of the Year - Issue 11 publication Ellen Lambrix and Marek Petecki in conversation with Brad...
Jan 18, 2024 The UK Government’s Autumn 2023 Statement – support for life sciences By Julia Cockroft Nick Cross This article is part of our Biotech Review of the Year - Issue 11 publication The UK Government has announced significant investment...